Answer to Question 1
Correct Answer: 2
Rationale 1: INR is incorrect because it should be monitored for a client receiving Coumadin therapy.
Rationale 2: To avoid serious adverse effects, drug therapy with coagulation-modifier drugs is individualized to each patient and must be carefully monitored. For heparin, the activated partial thromboplastin time (aPTT) is used.
Rationale 3: BNP is incorrect because this lab result does not pertain to clotting.
Rationale 4: PT is incorrect because it should be monitored for a client receiving Coumadin therapy.
Global Rationale: To avoid serious adverse effects, drug therapy with coagulation-modifier drugs is individualized to each patient, and must be carefully monitored. For heparin, the activated partial thromboplastin time (aPTT) is used. PT and INR is incorrect because they should be monitored for a client receiving Coumadin therapy. BNP is incorrect because this lab result does not pertain to clotting.
Answer to Question 2
Correct Answer: 2
Rationale 1: PT is incorrect because it should be monitored with INR for a client receiving Coumadin therapy.
Rationale 2: PT and INR should be monitored for a client receiving Coumadin therapy.
Rationale 3: BNP is incorrect because this lab result does not pertain to clotting.
Rationale 4: aPTT is incorrect because this should be monitored for a client receiving heparin therapy.
Global Rationale: PT and INR should be monitored for a client receiving Coumadin therapy. PT is incorrect because it should be monitored with INR for a client receiving Coumadin therapy. BNP is incorrect because this lab result does not pertain to clotting. aPTT is incorrect because this should be monitored for a client receiving heparin therapy.